Jamie Dananberg is Chief Medical Officer at Unity Biotechnology, Inc. (UBX). They have made 3 open-market trades across 1 company since 2022, most recently 2026-03-02.
CIK 0001734424
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANNX | 123,582 | $422K |
| UBX | 62,817 | $13K |
| Total | $435K |
Shares reported on the most recent Form 4, priced at the 2026-03-04 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANNX | SELL | 2026-03-02 | 2026-03-04 | $5.43 | $32K | +4.4% | +5.8% | -4.0% |
| ANNX | SELL | 2026-02-18 | 2026-02-20 | $5.10 | $27K | +14.3% | +9.8% | +11.7% |
| ANNX | SELL | 2025-02-18 | 2025-02-20 | $2.96 | $16K | -14.5% | -6.6% | -31.8% |
| UBX | SELL · 10b5-1 | 2023-03-31 | 2023-04-03 | $1.70 | $714 | +28.1% | +51.0% | +77.8% |
| UBX | SELL · 10b5-1 | 2023-03-14 | 2023-03-15 | $4.00 | $4K | -53.1% | -52.9% | -18.3% |
| UBX | SELL · 10b5-1 | 2023-02-02 | 2023-02-03 | $4.84 | $4K | -14.3% | -7.9% | -54.9% |
| UBX | SELL · 10b5-1 | 2022-12-14 | 2022-12-15 | $2.85 | $3K | -5.1% | +48.0% | +49.8% |
| UBX | SELL · 10b5-1 | 2022-09-14 | 2022-09-15 | $0.48 | $5K | -13.4% | -11.8% | -40.3% |
| UBX | SELL · 10b5-1 | 2022-06-27 | 2022-06-28 | $0.59 | $3K | -2.0% | +13.5% | -33.8% |
| UBX | SELL · 10b5-1 | 2022-06-21 | 2022-06-22 | $0.62 | $2K | -1.5% | +9.0% | -27.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.